Cargando…

Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y(12) receptor between selatogrel and oral P2Y(12) antagonists

Selatogrel is a potent and reversible P2Y(12) receptor antagonist developed for subcutaneous self‐administration by patients with suspected acute myocardial infarction. After single‐dose emergency treatment with selatogrel, patients are switched to long‐term treatment with oral P2Y(12) receptor anta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Henrich, Andrea, Claussen, Christian Hove, Dingemanse, Jasper, Krause, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8302241/ https://www.ncbi.nlm.nih.gov/pubmed/33955698 http://dx.doi.org/10.1002/psp4.12641

Ejemplares similares

Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel
por: Schilling, Uta, et al.
Publicado: (2022)

Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor Antagonists
por: Hsin, Chih-hsuan, et al.
Publicado: (2023)

Effect of Rifampin‐Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel
por: Schilling, Uta, et al.
Publicado: (2020)

The P2Y12 Receptor Antagonist Selatogrel Dissolves Preformed Platelet Thrombi In Vivo
por: Crescence, Lydie, et al.
Publicado: (2021)

Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y(12) receptor antagonist, in patients with chronic coronary syndromes
por: Storey, Robert F, et al.
Publicado: (2019)

Comparison of the effects of the GPIIb-IIIa antagonist Zalunfiban and the P2Y12 antagonist Selatogrel on Platelet Aggregation
por: Curry, Benjamin J., et al.
Publicado: (2023)

Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers
por: Li, Xiaojiao, et al.
Publicado: (2018)

To Pretreat or Not to Pretreat (With Oral P2Y12 Antagonists)? That is the Question
por: Lowenstern, Angela, et al.
Publicado: (2017)

Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan
por: Sidharta, P. N., et al.
Publicado: (2015)

Ticagrelor: The First Reversibly Binding Oral P2Y(12) Receptor Antagonist
por: Husted, Steen, et al.
Publicado: (2009)

Predicting the Effects of CYP2C19 and Carboxylesterases on Vicagrel, a Novel P2Y12 Antagonist, by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Approach
por: Liu, Shuaibing, et al.
Publicado: (2020)

Corrigendum: Predicting the Effects of CYP2C19 and Carboxylesterases on Vicagrel, a Novel P2Y12 Antagonist, by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Approach
por: Liu, Shuaibing, et al.
Publicado: (2021)

Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist
por: Krause, Andreas, et al.
Publicado: (2022)

Absence of Pharmacokinetic and Pharmacodynamic Interactions between Almorexant and Warfarin in Healthy Subjects
por: Dingemanse, Jasper, et al.
Publicado: (2013)

The P2Y(12) Antagonists, 2MeSAMP and Cangrelor, Inhibit Platelet Activation through P2Y(12)/G(i)-Dependent Mechanism
por: Xiang, Binggang, et al.
Publicado: (2012)

Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects
por: Sidharta, Patricia N, et al.
Publicado: (2019)

Pharmacokinetics and Pharmacodynamics of Cenerimod, A Selective S1P(1)R Modulator, Are Not Affected by Ethnicity in Healthy Asian and White Subjects
por: Juif, Pierre‐Eric, et al.
Publicado: (2020)

Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelion‐451840 in an induced blood stage malaria study in healthy subjects
por: Krause, Andreas, et al.
Publicado: (2016)

Identification of a New Morpholine Scaffold as a P2Y12 Receptor Antagonist
por: Ahn, Young Ha, et al.
Publicado: (2016)

Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P(1) Receptor Modulator in Healthy Subjects
por: Juif, Pierre-Eric, et al.
Publicado: (2017)

Salvianolic acids from antithrombotic Traditional Chinese Medicine Danshen are antagonists of human P2Y(1) and P2Y(12) receptors
por: Liu, Xuyang, et al.
Publicado: (2018)

P2Y12 inhibitors for the neurointerventionalist
por: Borchert, Robin J, et al.
Publicado: (2021)

P2Y(12) Receptor Antagonist Clopidogrel Attenuates Lung Inflammation Triggered by Silica Particles
por: Santana, Patricia Teixeira, et al.
Publicado: (2020)

P2Y(12) Receptors in Tumorigenesis and Metastasis
por: Ballerini, Patrizia, et al.
Publicado: (2018)

Author Correction: Salvianolic acids from antithrombotic Traditional Chinese Medicine Danshen are antagonists of human P2Y(1) and P2Y(12) receptors
por: Liu, Xuyang, et al.
Publicado: (2018)

A pharmacodynamic study of the optimal P2Y(12) inhibitor regimen for East Asian patients with acute coronary syndrome
por: Lee, Ji Hyun, et al.
Publicado: (2015)

D121 Located within the DRY Motif of P2Y12 Is Essential for P2Y12-Mediated Platelet Function
por: Dangelmaier, Carol, et al.
Publicado: (2022)

P2Y12 antagonist attenuates eosinophilic inflammation and airway hyperresponsiveness in a mouse model of asthma
por: Suh, Dong‐Hyeon, et al.
Publicado: (2015)

P2Y12 Receptor Antagonist, Clopidogrel, Does Not Contribute to Risk of Osteoporotic Fractures in Stroke Patients
por: Jørgensen, Niklas R., et al.
Publicado: (2017)

Platelet Reactivity And Circulating Platelet-Derived Microvesicles Are Differently Affected By P2Y(12) Receptor Antagonists
por: Chyrchel, Bernadeta, et al.
Publicado: (2019)

P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets
por: Gasecka, Aleksandra, et al.
Publicado: (2020)

Selective and rapid monitoring of dual platelet inhibition by aspirin and P2Y(12 )antagonists by using multiple electrode aggregometry
por: Penz, Sandra M, et al.
Publicado: (2010)

Oral Delivery of the P2Y(12) Receptor Antagonist Ticagrelor Prevents Loss of Photoreceptors in an ABCA4(−/−) Mouse Model of Retinal Degeneration
por: Lu, Wennan, et al.
Publicado: (2019)

Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment
por: Berger, Benjamin, et al.
Publicado: (2021)

Lack of Effect of Cenerimod, a Selective S1P(1) Receptor Modulator, on the Pharmacokinetics of a Combined Oral Contraceptive
por: Juif, Pierre-Eric, et al.
Publicado: (2022)

Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors
por: Ristorto, Jessica, et al.
Publicado: (2018)

Disposition and Metabolism of Setipiprant, a Selective Oral CRTH2 Antagonist, in Humans
por: Hoch, Matthias, et al.
Publicado: (2013)

GRK2 regulates ADP signaling in platelets via P2Y(1) and P2Y(12)
por: Zhao, Xuefei, et al.
Publicado: (2022)

The Use Pattern and Clinical Impact of Novel P2Y12 Receptor Antagonists for Acute Myocardial Infarction in Korea
por: Kim, Soo-Joong
Publicado: (2017)

DT‐678 inhibits platelet activation with lower tendency for bleeding compared to existing P2Y(12) antagonists
por: Lauver, Dale A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qcc1f29l7ep9edjn48fmsotusq